This is a routine, pre-planned insider sale under a 10b5-1 plan. The small size and pre-arranged nature suggest no negative signal. Monitor for any acceleration of insider selling or unexpected Form 4 filings that could indicate a change in sentiment.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 25 $69.69entry
- T+1 · 5mo ago +0.79%α +1.51% · $70.24
- T+5 · 5mo ago +6.93%α +5.37% · $74.52
- T+20 · 4mo ago +19.00%α +18.47% · $82.93
- T+60 · 8w ago −4.42%α −8.15% · $66.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio Pharma director Randal Scott filed a Form 144 notice of intent to sell 2,196 shares of common stock, with an estimated aggregate market value of approximately $150,711. The shares were acquired via restricted stock units that vested on June 20, 2026. The sale is being conducted under a Rule 10b5-1 trading plan established on June 27, 2025, which mitigates concerns about opportunistic timing. The proposed sale represents a de minimis portion of Scott's holdings relative to the company's $13.6B market cap and is consistent with routine insider diversification.
Key Facts
- Director Randal Scott filed Form 144 to sell 2,196 shares of BBIO common stock.
- Estimated aggregate market value of the proposed sale is approximately $150,711.
- Shares were acquired through restricted stock units that vested on June 20, 2026.
- Sale is being executed under a Rule 10b5-1 trading plan dated June 27, 2025.
- The proposed sale represents less than 0.001% of BBIO's $13.6B market capitalization.
- Recent insider activity (30d) shows 3 sells totaling $2.9M, indicating ongoing but modest insider selling.
Financial Impact
Proposed sale of 2,196 shares valued at ~$150,711, immaterial relative to $13.6B market cap.
Risk Factors
- Insider selling pattern could accelerate if additional Form 144s or Form 4s are filed by other executives.
- The 10b5-1 plan was established nearly a year ago, so the sale is not reactive to current fundamentals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006457 |
| Document: 0001950047-26-006457-index.html | 0001950047-26-006457 |
| Document: 0001950047-26-006457.txt | 0001950047-26-006457 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers